EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.

Sebastian Michels,Lucia Nogova,Barbara Deschler-Baier,Enriqueta Felip,Delvys Rodriguez Abreu,Rafael Rosell,Martin Sebastian,Martin Schuler,Martin Wermke,Rieke Fischer,Sophia Koleczko,Diana S.Y. Abdulla,R. Riedel,Matthias Scheffler,Jana Fassunke,Martin Hellmich,Sabine Merkelbach-Bruse,Reinhard Buettner,Juergen Wolf

EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.

2019

Sebastian Michels
Lucia Nogova
Barbara Deschler-Baier
Enriqueta Felip
Delvys Rodriguez Abreu
Rafael Rosell
Martin Sebastian
Martin Schuler
Martin Wermke
Rieke Fischer
Sophia Koleczko
Diana S.Y. Abdulla
R. Riedel
Matthias Scheffler
Jana Fassunke
Martin Hellmich
Sabine Merkelbach-Bruse
Reinhard Buettner
Juergen Wolf

e20577Background: Multiple mechanisms of resistance to EGFR TKIs therapy in EGFR-mutant non-small cell lung cancer (NSCLC) have been described, most often including the acquisition of the secondary...

Keywords:

Lung cancer
Cell
Trametinib
Oncology
Pathology
Mutant
Tolerability
Medicine
Internal medicine
in patient
open label
non small cell
dose escalation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations